These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 15168801

  • 21. The quest for an efficacious antiviral for respiratory syncytial virus.
    Torrence PF, Powell LD.
    Antivir Chem Chemother; 2002 Nov; 13(6):325-44. PubMed ID: 12718405
    [Abstract] [Full Text] [Related]

  • 22. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin.
    Kim YI, Pareek R, Murphy R, Harrison L, Farrell E, Cook R, DeVincenzo J.
    Influenza Other Respir Viruses; 2017 Nov; 11(6):525-530. PubMed ID: 28990339
    [Abstract] [Full Text] [Related]

  • 23. Detection and quantitation of human respiratory syncytial virus (RSV) using minigenome cDNA and a Sindbis virus replicon: a prototype assay for negative-strand RNA viruses.
    Olivo PD, Collins PL, Peeples ME, Schlesinger S.
    Virology; 1998 Nov 10; 251(1):198-205. PubMed ID: 9813215
    [Abstract] [Full Text] [Related]

  • 24. 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection.
    Torrence PF.
    Curr Opin Mol Ther; 1999 Jun 10; 1(3):307-15. PubMed ID: 11713795
    [Abstract] [Full Text] [Related]

  • 25. Antiviral activity and mode of action of caffeoylquinic acids from Schefflera heptaphylla (L.) Frodin.
    Li Y, But PP, Ooi VE.
    Antiviral Res; 2005 Oct 10; 68(1):1-9. PubMed ID: 16140400
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.
    Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE.
    Antiviral Res; 1997 Feb 10; 33(3):201-13. PubMed ID: 9037376
    [Abstract] [Full Text] [Related]

  • 27. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec 10; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

  • 28. Controlling gene expression with 2-5A antisense.
    Leaman DW, Cramer H.
    Methods; 1999 Jul 10; 18(3):252-65. PubMed ID: 10454983
    [Abstract] [Full Text] [Related]

  • 29. [The anti-respiratory syncytial virus effect of an active compound (AP3) from a Chinese medicinal herb-Herba patriniae in vitro].
    Li SS, Li HY, Piao YA, Liu DL, Tian WJ, Dong YM.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Feb 10; 25(2):150-3. PubMed ID: 15132871
    [Abstract] [Full Text] [Related]

  • 30. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
    Ottolini MG, Curtis SR, Mathews A, Ottolini SR, Prince GA.
    Bone Marrow Transplant; 2002 Jan 10; 29(2):117-20. PubMed ID: 11850705
    [Abstract] [Full Text] [Related]

  • 31. Respiratory syncytial virus infection in adults.
    Falsey AR.
    Semin Respir Crit Care Med; 2007 Apr 10; 28(2):171-81. PubMed ID: 17458771
    [Abstract] [Full Text] [Related]

  • 32. Novel therapies for an old virus: treatment of RSV infections in the 21st Century.
    Lüsebrink J, Schildgen V, Schildgen O.
    Expert Rev Anti Infect Ther; 2009 Nov 10; 7(9):1125-9. PubMed ID: 19883332
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
    Detrick B, Nagineni CN, Grillone LR, Anderson KP, Henry SP, Hooks JJ.
    Invest Ophthalmol Vis Sci; 2001 Jan 10; 42(1):163-9. PubMed ID: 11133862
    [Abstract] [Full Text] [Related]

  • 34. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.
    Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, Malouf MA.
    J Heart Lung Transplant; 2005 Dec 10; 24(12):2114-9. PubMed ID: 16364859
    [Abstract] [Full Text] [Related]

  • 35. RSV infections: developments in the search for new drugs.
    Torrence PF.
    Drug News Perspect; 2000 May 10; 13(4):226-33. PubMed ID: 12937627
    [Abstract] [Full Text] [Related]

  • 36. Effect of nitrogen dioxide on respiratory viral infection in airway epithelial cells.
    Becker S, Soukup JM.
    Environ Res; 1999 Aug 10; 81(2):159-66. PubMed ID: 10433848
    [Abstract] [Full Text] [Related]

  • 37. Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy.
    Adah SA, Bayly SF, Cramer H, Silverman RH, Torrence PF.
    Curr Med Chem; 2001 Aug 10; 8(10):1189-212. PubMed ID: 11472236
    [Abstract] [Full Text] [Related]

  • 38. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells.
    Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, Brasier AR.
    J Virol; 2003 May 10; 77(10):5933-47. PubMed ID: 12719586
    [Abstract] [Full Text] [Related]

  • 39. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
    Bolger G, Lapeyre N, Dansereau N, Lagacé L, Berry G, Klosowski K, Mewhort T, Liuzzi M.
    Can J Physiol Pharmacol; 2005 Feb 10; 83(2):198-213. PubMed ID: 15791294
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.